ClinVar Miner

Submissions for variant NM_015560.2(OPA1):c.2708_2711delTTAG (rs80356530)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000081763 SCV000228466 pathogenic not provided 2017-01-12 criteria provided, single submitter clinical testing
GeneDx RCV000081763 SCV000252013 pathogenic not provided 2017-11-02 criteria provided, single submitter clinical testing The c.2708_2711delTTAG variant has been reported multiple times in association with autosomal dominant optic atrophy (Delettre et al., 2000; Toomes et al., 2001). This variant has also been reported in a patient with optic atrophy plus spastic paraplegia, Duane retraction syndrome, migraine with atypical aura, patent foramen ovale, and muscle fibre abnormalities (Pretegiani et al., 2011). An Opa1 mouse model carrying the c.2708_2711delTTAG variant displayed a multi-systemic poly-degenerative phenotype including signs of visual failure, deafness, encephalomyopathy, peripheral neuropathy, ataxia, cardiomyopathy, and premature age-related axonal and myelin degenerations (Sarzi et al., 2012). The deletion causes a frameshift starting with codon Valine 903, changes this amino acid to a Glycine residue and creates a premature Stop codon at position 3 of the new reading frame, denoted p.Val903GlyfsX3. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. In summary, we interpret c.2708_2711delTTAG to be a pathogenic variant.
Athena Diagnostics Inc RCV000081763 SCV000614384 pathogenic not provided 2015-09-18 criteria provided, single submitter clinical testing
Center of Genomic medicine, Geneva,University Hospital of Geneva RCV000005387 SCV000693465 pathogenic Dominant hereditary optic atrophy 2017-09-18 criteria provided, single submitter clinical testing This frameshift variant (deletion of four nucleotides) in the OPA1 gene was identified in a male young patient and also his mother, both diagnosed with optic atrophy 1.
OMIM RCV000005387 SCV000025567 pathogenic Dominant hereditary optic atrophy 2011-08-01 no assertion criteria provided literature only
GeneReviews RCV000005387 SCV000041284 pathogenic Dominant hereditary optic atrophy 2015-11-12 no assertion criteria provided literature only
OMIM RCV000210745 SCV000266834 pathogenic Abortive cerebellar ataxia 2011-08-01 no assertion criteria provided literature only
Wellcome Centre for Mitochondrial Research,Newcastle University RCV000508703 SCV000575923 pathogenic Mitochondrial diseases 2017-04-07 no assertion criteria provided clinical testing
GenomeConnect, ClinGen RCV000005387 SCV000606947 not provided Dominant hereditary optic atrophy no assertion provided phenotyping only GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.